The company said it plans to list its common shares and warrants on the NYSE American while pursuing a concurrent underwritten public offering, subject to regulatory approvals and market conditions.
Devonian Health Group said it is conducting an underwritten public offering of common shares and/or pre-funded warrants in lieu thereof, together with warrants, while seeking approval to list its common shares and warrants on the NYSE American under the symbols DHGR and DHGRW. The offering remains subject to market conditions and regulatory approval, and the company said there is no assurance on timing, size or final terms. Devonian expects its common shares to continue trading on the OTCQB Venture Market until the offering is priced, after which OTCQB trading would end upon a NYSE American listing. The company has also reserved the symbol DHGR on the TSX Venture Exchange and intends to request a later ticker change from GSD to DHGR. ThinkEquity is acting as sole book-running manager. Devonian, a clinical-stage biopharmaceutical company focused on fibro-inflammatory and autoimmune diseases, said additional details will be provided through filings with the SEC and Canadian securities regulators.